Kolistin a otázky jeho terapeutického monitoringu
| Title in English | Colistin and issues of its therapeutic monitoring |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Colistin falls within the pharmacokinetic-pharmacodynamic (PK/PD) profile of exposure-dependent antibiotics, with a target AUCSS,0-24/MIC of approximately 50 mg*h/l, or a total steady-state plasma concentration of approximately 2 mg/l. Colistin also exhibits dose-dependent nephrotoxicity. Determination of plasma concentrations of colistin is available in routine clinical practice, however, the timing of sampling for modelling and calculation of AUC and the interpretation of measurements is associated with a number of issues. In this communication, in addition to stability issues, we will mainly focus on the pharmacokinetic characteristics of colistin methansulfonate as a prodrug and colistin as its own active product, whether monitoring of the prodrug is appropriate or whether measurement of colistin is sufficient, or when TDM of colistin is actually desirable in clinical practice. |
| Related projects: |